SCHEMBL5225607

SCHEMBL5225607

CN1CCC([Mg]Br)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1600880 0.72
SCHEMBL12001 0.71
SCHEMBL7073887 0.67
SCHEMBL2735017 0.65 GNAI3 (0.50)
SCHEMBL8130721 0.65
SCHEMBL19449598 0.65
SCHEMBL12435319 0.63 NCF1 (0.46)
SCHEMBL13400 0.63
SCHEMBL13775366 0.63 NCF1 (0.46)
SCHEMBL9965910 0.63 GNAI3 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3356344-B1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY ASTEX THERAPEUTICS LTD (GB) 2022-11-16 EP disclosed
US-20220106287-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY ASTEX THERAPEUTICS LIMITED (GB) 2022-04-07 US disclosed
US-11261171-B1 Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity ASTEX THERAPEUTICS LIMITED (GB) 2022-03-01 US disclosed
US-20190055215-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY ASTEX THERAPEUTICS LIMITED (GB) 2019-02-21 US disclosed
EP-3356344-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY Astex Therapeutics Ltd (GB) 2018-08-08 EP disclosed
EP-0819121-B1 TRICYCLIC COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES SCHERING CORP (US) 2007-05-30 EP disclosed
EP-0815100-B1 TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES SCHERING CORP (US) 2006-06-21 EP disclosed
US-20030055065-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases BISHOP W ROBERT (US) 2003-03-20 US disclosed
US-20020068742-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases BISHOP W ROBERT (US) 2002-06-06 US disclosed
US-6365588-B1 AS ANTINEOPLASTIC AGENT AND A POTENTIATING SCHERING CORPORATION 2002-04-02 US disclosed
US-5599816-A BACTERICIDE ABBOTT LABORATORIES (US) 1997-02-04 US disclosed
WO-1996039407-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1996-12-12 WO disclosed
US-5580872-A ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS ABBOTT LABORATORIES (US) 1996-12-03 US disclosed
WO-1996031478-A1 TRICYCLIC COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES SCHERING CORPORATION (US) 1996-10-10 WO disclosed
WO-1996030363-A1 TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES SCHERING CORPORATION (US) 1996-10-03 WO disclosed
EP-0723545-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1996-07-31 EP disclosed
WO-1995010519-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1995-04-20 WO disclosed
EP-0527889-A4 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LAB (US) 1994-08-10 EP disclosed
EP-0527889-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1993-02-24 EP disclosed
WO-1991016894-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1991-11-14 WO disclosed